Aralez Pharmaceuticals Inc. (NASDAQ:ARLZ)‘s stock had its “positive” rating reiterated by investment analysts at Guggenheim in a research note issued to investors on Tuesday.
Separately, Chardan Capital restated a “buy” rating and set a $10.00 price target on shares of Aralez Pharmaceuticals in a research report on Friday, September 16th.
Aralez Pharmaceuticals (NASDAQ:ARLZ) opened at 5.06 on Tuesday. The firm’s market cap is $330.12 million. Aralez Pharmaceuticals has a 52-week low of $3.10 and a 52-week high of $8.59. The company’s 50-day moving average price is $5.28 and its 200-day moving average price is $4.14.
Aralez Pharmaceuticals (NASDAQ:ARLZ) last posted its quarterly earnings results on Tuesday, August 9th. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.19) by $0.08. The firm earned $12.60 million during the quarter, compared to analyst estimates of $9.70 million. Aralez Pharmaceuticals had a negative net margin of 224.35% and a negative return on equity of 73.21%. The firm’s revenue for the quarter was up 142.3% on a year-over-year basis. Analysts predict that Aralez Pharmaceuticals will post ($1.05) EPS for the current year.
In other Aralez Pharmaceuticals news, Director Robert Paul Harris sold 150,000 shares of the company’s stock in a transaction on Thursday, September 15th. The stock was sold at an average price of $5.82, for a total transaction of $873,000.00. Following the transaction, the director now owns 669,094 shares of the company’s stock, valued at approximately $3,894,127.08. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Company insiders own 6.77% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of ARLZ. BlackRock Institutional Trust Company N.A. bought a new position in Aralez Pharmaceuticals during the first quarter worth $1,656,000. Contrarius Investment Management Ltd bought a new position in Aralez Pharmaceuticals during the first quarter worth $1,455,000. State Street Corp increased its position in Aralez Pharmaceuticals by 58.4% in the first quarter. State Street Corp now owns 790,730 shares of the company’s stock worth $2,808,000 after buying an additional 291,595 shares during the period. Geode Capital Management LLC bought a new position in Aralez Pharmaceuticals during the first quarter worth $273,000. Finally, Renaissance Technologies LLC bought a new position in Aralez Pharmaceuticals during the first quarter worth $2,168,000. 49.63% of the stock is currently owned by hedge funds and other institutional investors.
About Aralez Pharmaceuticals
Aralez Pharmaceuticals Inc is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G.
Receive News & Ratings for Aralez Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aralez Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.